Carrick Therapeutics has announced that it has licensed exclusive worldwide rights to develop and commercialise the targeted ovarian cancer drug CT900 from BTG.
CT900 is a targeted therapy inhibitor, targeting tumour cells that over-express the alpha folate receptor, and subsequently inhibiting thymidylate synthase.
The compound, previously known as BTG-945, was discovered at the CRUK Cancer Therapeutics Unit at The Institute of Cancer Research, London. A license and collaboration agreement with BTG conducted by CRUK’s Commercial Partnerships group (previously CRT) enabled the pre-clinical development programme which BTG then carried forward towards entry into the clinic.
An early phase 1 trial led by the Institute of Cancer Research (ICR) and The Royal Marsden hospital produced promising data, resulting in Carrick preparing to commence the pivotal studies. Carrick will additionally undertake a clinical development programme in other cancers.
Commenting on CT900, Professor Paul Workman, Chief Executive and President of the ICR, said: “I am very excited that this drug is progressing to the next stage of clinical trials and believe it has the potential to be a highly effective treatment for women with ovarian cancer, even when their tumours have become resistant to existing drugs.”